Three of the nation’s major drug manufacturers sued the Trump administration on Friday to block a rule that would force them to put the price of their drugs in television advertisements beginning this summer.

The lawsuit, filed Friday in federal court in Washington, D.C., by Merck, Eli Lilly and Amgen, as well as a trade group for advertisers, argues that the rule is illegal because it violates the companies’ First Amendment rights. It also claims that the ad disclosures, which require drug manufacturers to include the list price of any drug that costs more than $35 a month, could mislead consumers because insurers often cover the bulk of a drug’s cost.

“We believe the new requirements may cause patients to decide not to seek treatment because of their perception that they cannot afford their medications, when in fact many patients do not pay anything near list price,” Merck, whose top-selling product is the pricey cancer drug Keytruda, said in a statement.

Lilly, which is one of three manufacturers of insulin under scrutiny for rising list prices — said the federal government had overstepped its authority. “The impetus for the lawsuit is drug prices in TV ads, but the crux of it is H.H.S. not having the authority to mandate this action,” the company said in a statement, referring to the Department of Health and Human Services.